Morphle Labs has raised a Series A funding of $5 million. This critical capital injection was led by Inflexor Ventures. The strategic uses of the Series A funds have been defined to fulfil two paramount functions of the company, namely to upgrade its core technological strengths and expand its commercial presence significantly in the global market.

Capital infusion and substantial investment

The $5 million Series A funding will be invested in four main strategic pillars, all of which will transform the company into a high-potential deeptech startup into an established commercial leader in its industry. A large part of the new funds raised is invested in the expansion of the production of the two main products of the company, RoboTome and MorphoLens, guaranteeing a significant increase in the size of the production capacity to satisfy the demands of the world audience. This manufacturing scale is critical to the intended expansion.

Morphle Labs also aims to obtain the required regulatory clearances from the appropriate authorities in the major overseas markets. These approvals are an important, non-negotiable requirement that will enable the firm to market and implement its diagnostic technologies in other jurisdictions, thereby expanding the market the company can address compared to its present areas of operation.

It will invest heavily in the acquisition of talent, in particular, strengthening its engineering and research forces. The company is also aggressively working on the expansion of its commercial presence, especially in the major markets in the United States and other parts of Europe, with the objective of having a strong international presence.

Core mission and flagship products

In 2017, Rohit Hiwale and Anchit Navelkar, the co-founders of Morphle Labs, decided to exploit advanced engineering capabilities to solve complicated problems in medical diagnostics. Since its inception, the company has been at the crossroads of several highly developed fields, integrating them to develop automated diagnostic technologies. Morphle Labs is a company that capitalizes on the power of robotics, incredibly precise hardware parts, sophisticated optics, and artificial intelligence (AI) to create innovative technologies, which are used to automate the process of tissue diagnostics.

Morphle Labs boasts of having registered a great portfolio of more than 80 patents. Such patent submissions are quite diverse and cover a broad spectrum of technology areas such as robotics, special optics, advanced embedded systems, and different types of imaging technology. This is the basis of its development and protection of its specialised position in the world market of automated medical equipment. The core mission of Morphle Labs, that is, to automate diagnostics, is reflected in the collection of flagship products, which are each focused on a particular, important stage of the diagnostic process. 

The first product, the RoboTome, deals with the manual, labor-intensive part of the process of tissue sample preparation. RoboTome is developed to automate the process of sectioning tissue blocks to extremely thin slices that can be put on the microscope slides. Automating this step also results in the fact that the pathologists end up with high-quality and clean slides, which is directly translated into more accurate and much faster insights, particularly in the case of complex diseases such as cancer.

The second product, MorphoLens, is a digital slide scanner that is an imaging scanner. It is a sophisticated tool that is needed to conduct a thorough and high-quality examination of tissues. Medical technicians and qualified doctors use MorphoLens widely, and they therefore have the necessary equipment to help identify the tiniest cell abnormality in the samples.

In addition to these two main products, the company has also developed a third specialized product called HemoLabs. The given product is specifically aimed at the blood diagnostics, at the accurate location and identification of the blood cells and other fragments of platelets, which is required in order to obtain the sorting and serious testing processes.

Conclusion

The successful closure of the Series A round of $5 million, led by Inflexor Ventures, is another major validation of the deep-tech approach to healthcare that Morphle Labs has adopted. This firm is set to boost its growth through the improvement of its patented technology, augmenting the production of groundbreaking products, such as RoboTome and MorphoLens, and gaining international regulatory approval. This successful fundraise is what puts Morphle Labs in a position to succeed within a growing group of healthcare-based deeptech startups that are raising early-stage capital.